37th week of 2013 patent applcation highlights part 38 |
Patent application number | Title | Published |
20130236357 | HYDROGEN PEROXIDE STERILIZATION METHOD - A method of metering of hydrogen peroxide gas into an evacuated sterilization chamber is disclosed. The method includes the steps of continuously monitoring a pressure in the sterilization chamber; connecting a passage of known volume to the evacuated chamber for evacuating the passage; sealing the passage; connecting the evacuated passage to a supply of hydrogen peroxide solution for a time sufficient to draw the hydrogen peroxide solution into and fill the passage; sealing the passage; and repeating those steps until a preselected pressure increase in the sterilization chamber is detected. The pressure increase is preferably 19 Torr. The known volume of the metering passage is preferably between 75 μL and 15 μL to control unwanted condensation of hydrogen peroxide in the sterilization chamber. Expensive peroxide concentration measurement systems are replaced with an economical low cost pressure sensor for control of the hydrogen peroxide concentration. | 2013-09-12 |
20130236358 | SYSTEM AND METHOD FOR VIRUS INACTIVATION - Methods and systems for virus inactivation in the production or processing of biological or other sensitive substances are provided. The disclosed methods and systems for virus inactivation involve the key steps of dissolving carbon dioxide into biological or other sensitive substances; and treating the substance with the dissolved carbon dioxide at conditions which are less than critical pressure and temperature for a prescribed treatment time to inactivate at least 80% of the target virus or viruses contained within the biological or other sensitive substances. The disclosed carbon dioxide treatments for virus inactivation may optionally include concurrently or sequentially subjecting the substances with an acid treatment to lower the pH of the substance and inactivate viruses contained within the biological or other sensitive substance. Operating conditions for the disclosed carbon dioxide treatments preferably involve sparging carbon dioxide gas into the substance until the composition is saturated with carbon dioxide and is conducted at pressures below about 5 MPa; at temperatures of less than or equal to 30° C.; and for a treatment time of between about one minute and about 2000 minutes. | 2013-09-12 |
20130236359 | METHODS FOR STERILIZATION IN A VACUUM SYSTEM - A method of sterilizing a vacuum system, comprising: creating a vacuum in a vacuum chamber such that a pressure differential is formed between the vacuum chamber and a liquid sterilant supply, and wherein the liquid sterilant supply has a higher pressure than the vacuum chamber; vaporizing liquid sterilant; and sterilizing the vacuum chamber with the vaporized sterilant. | 2013-09-12 |
20130236360 | AUTOMATIC ANALYZER USING A SAMPLE CONTAINER HAVING AN INFORMATION RECORDING MEMBER - A sample is contained in a sample container and a physical relationship between the sample and a sample ID thereof is established. However, after the sample ID is read by a bar code reader and the sample is transferred to an analysis-dedicated small sample container, the sample ID and the sample are separated from each other. Following the end of analysis, therefore, the sample ID must be merged with a corresponding analysis result. A read/write-enable ID carrier is provided on an analysis-dedicated sample container into which the sample is pipetted or on a tank for holding the analysis-dedicated sample container. When the sample is pipetted or when the analysis-dedicated sample container is moved, the sample ID and other information are transferred to the read/write-enable ID carrier. | 2013-09-12 |
20130236361 | HEATING COMBUSTION TUBE, PYROLYSIS APPARATUS AND MERCURY ANALYZING APPARATUS IN ANALYSIS OF MERCURY - A heating combustion tube | 2013-09-12 |
20130236362 | VACUUM ULTRAVIOLET PHOTOIONIZATION AND CHEMICAL IONIZATION COMBINED ION SOURCE FOR MASS SPECTROMETRY - This invention relates to the field of mass spectrometry, and more specifically to a vacuum ultraviolet photoionization and chemical ionization combined ion source, which consists of a vacuum ultraviolet light source and an ion source chamber. An ion acceleration electrode, an ion repulsion electrode, an ion extraction electrode, and a differential interface electrode positioned inside the ion source chamber are arranged along the exit direction of the vacuum ultraviolet light beam in sequence and spaced, coaxial, and parallel from each other. The ion acceleration electrode, the ion repulsion electrode, the ion extraction electrode, and the differential interface electrode are all plate structures with central through holes. The vacuum ultraviolet light beam passes through the central through holes of the electrodes along the axial direction. By utilizing a single vacuum ultraviolet light source, the ion source is feasible to switch between two ionization modes, vacuum ultraviolet photoionization (VUV PI) and chemical ionization (CI), under suitable ion source pressure, thus greatly expanding the range of detectable samples. | 2013-09-12 |
20130236363 | STERILIZATION APPARATUS - A hydrogen peroxide delivery system for a sterilizer having a hydrogen peroxide injection unit and a housing is disclosed. The system includes a cradle for supporting a hydrogen peroxide solution container, a drainage arrangement for aspirating the hydrogen peroxide solution from the container, and a delivery arrangement for supplying the aspirated hydrogen peroxide solution to the hydrogen peroxide injection unit. The drainage arrangement includes a needle for penetrating a seal on the container and extending into the hydrogen peroxide solution in the container. A needle drive moves the needle from an at rest position, wherein the needle is retracted to allow insertion of a new hydrogen peroxide container into the cradle, to a penetrating position wherein the needle penetrates the seal of the container and extends all the way to the bottom of the container to ensure complete drainage of the hydrogen peroxide solution from the container. | 2013-09-12 |
20130236364 | EXHAUST PURIFYING APPARATUS IN INTERNAL COMBUSTION ENGINE - The present invention provides an exhaust purifying apparatus in an internal combustion engine provided with an exhaust treatment device in an exhaust passage. The exhaust purifying apparatus comprises an oxidation device provided upstream of the exhaust treatment device, a fuel adding valve for adding fuel upstream of the oxidation device, and a glow plug provided upstream of the oxidation device for heating the fuel added from the fuel adding valve. The oxidation device is formed to be provided with gas passages the number of which is equal to or more than 30 and is equal to or less than 200 per 0.00064516 m | 2013-09-12 |
20130236365 | ADSORPTIVE PHOTO-CATALYTIC OXIDATION AIR PURIFICATION DEVICE - An air purification system formed from an adsorptive photo-catalytic oxidation device and a method of regenerating the oxidation device is disclosed. The air purification may be configured to be installed within an air duct of a central air handling system. The air purification system may also include an ultraviolet light emitted by the ultraviolet light source to breakdown captured volatile organic compounds into elemental carbon dioxide and water vapor and to irradiate air moving past the ultraviolet light and surfaces to reduce contaminants The ultraviolet light source may be positioned to expose the adsorptive photo-catalytic oxidation device to ultraviolet light emitted by the ultraviolet light source to breakdown captured volatile organic compounds into elemental carbon dioxide and water vapor and to irradiate air moving past the ultraviolet light to reduce contaminants. | 2013-09-12 |
20130236366 | CONDENSATION AND WASHING DEVICE, POLYMERISATION DEVICE AND METHOD FOR CLEANING PROCESS STEAM DURING THE PRODUCTION OF POLYLACTIDE - The present invention relates to a condensation and washing device with which in particular the process vapours which occur during the production of polylactide can be processed and cleaned. Furthermore, the present invention relates to a polymerisation device for the production of polylactide and also to a method for processing process vapours which occur during the production of polylactide; possibilities for use of both the condensation and washing devices and of the method are likewise mentioned. | 2013-09-12 |
20130236367 | PRODUCTION OF POLYCRYSTALLINE SILICON IN SUBSTANTIALLY CLOSED-LOOP SYSTEMS - Production of polycrystalline silicon in a substantially closed-loop process is disclosed. The processes generally include decomposition of trichlorosilane produced from metallurgical grade silicon. | 2013-09-12 |
20130236368 | DOUBLE HELIX TYPE GAS HYDRATE REACTOR - A double helix gas hydrate reactor is disclosed. The reactor includes an inlet port ( | 2013-09-12 |
20130236369 | GRADUAL OXIDATION WITH HEAT EXCHANGE MEDIA - Described herein are embodiments of systems and methods for oxidizing gases. In some embodiments, a reaction chamber is configured to receive a fuel gas and maintain the gas at a temperature within the reaction chamber that is above an autoignition temperature of the gas. The reaction chamber may also be configured to maintain a reaction temperature within the reaction chamber below a flameout temperature. In some embodiments, heat and product gases from the oxidation process can be used, for example, to drive a turbine, reciprocating engine, and injected back into the reaction chamber. | 2013-09-12 |
20130236370 | GRADUAL OXIDATION BELOW FLAMEOUT TEMPERATURE - Described herein are embodiments of systems and methods for oxidizing gases. In some embodiments, a reaction chamber is configured to receive a fuel gas and maintain the gas at a temperature within the reaction chamber that is above an autoignition temperature of the gas. The reaction chamber may also be configured to maintain a reaction temperature within the reaction chamber below a flameout temperature. In some embodiments, heat and product gases from the oxidation process can be used, for example, to drive a turbine, reciprocating engine, and injected back into the reaction chamber. | 2013-09-12 |
20130236371 | GRADUAL OXIDATION WITH ADIABATIC TEMPERATURE ABOVE FLAMEOUT TEMPERATURE - Described herein are embodiments of systems and methods for oxidizing gases. In some embodiments, a reaction chamber is configured to receive a fuel gas and maintain the gas at a temperature within the reaction chamber that is above an autoignition temperature of the gas. The reaction chamber may also be configured to maintain a reaction temperature within the reaction chamber below a flameout temperature. In some embodiments, heat and product gases from the oxidation process can be used, for example, to drive a turbine, reciprocating engine, and injected back into the reaction chamber. | 2013-09-12 |
20130236372 | GRADUAL OXIDATION AND MULTIPLE FLOW PATHS - Described herein are embodiments of systems and methods for oxidizing gases. In some embodiments, a reaction chamber is configured to receive a fuel gas and maintain the gas at a temperature within the reaction chamber that is above an autoignition temperature of the gas. The reaction chamber may also be configured to maintain a reaction temperature within the reaction chamber below a flameout temperature. In some embodiments, heat and product gases from the oxidation process can be used, for example, to drive a turbine, reciprocating engine, and injected back into the reaction chamber. | 2013-09-12 |
20130236373 | HYDROGEN PEROXIDE STERILIZATION METHOD - A metering unit is provided for metering hydrogen peroxide into an evacuated vessel, for controlling the concentration of hydrogen peroxide in the vessel. The metering unit includes a body defining a metering passage having a fixed volume and upstream and downstream ends, an upstream connection for connecting the upstream end to a hydrogen peroxide supply, a downstream connection for connecting the downstream end to a hydrogen peroxide vaporizer, an upstream valve for selectively closing the upstream end and a downstream valve for selectively closing the downstream end, and a controller for operating the valves in a non-overlapping and opposite manner for selectively preventing opening of both valves at the same time. With the metering unit of this disclosure, expensive peroxide concentration measurement systems are replaced with an economical monitoring of the number of injection cycles using a passage of fixed volume. | 2013-09-12 |
20130236374 | FLUID CARTRIDGE AND SYSTEM FOR DISPENSING FLUID - A fluid cartridge has a bottle to retain a volume of fluid. An ejector chip resides in fluid communication with the bottle and causes ejection of fluid upon activation of fluid ejectors. Control logic coordinates ejector activation with dose control logic and temperature control circuitry. The dose control logic pre-specifies an amount of fluid to be ejected and prevents further ejection upon reaching the amount. Meanwhile, the temperature control circuit inhibits any ejection until a temperature of the fluid is within a predefined acceptable range. Bottle modularity, fluid dispense-areas and group-control of the ejectors facilitate certain designs. | 2013-09-12 |
20130236375 | FLUID MIXING AND DELIVERY IN MICROFLUIDIC SYSTEMS - The specification generally discloses systems and methods for mixing and delivering fluids in microfluidic systems. The fluids can contain, in some embodiments reagents that can participate in one or more chemical or biological reactions. Some embodiments relate to systems and methods employing one or more vent valves to controllably flow and/or mix portions of fluid within the microfluidic system. Advantageously, fluid control such as a sequence of fluid flow and/or a change in flow rate, can be achieved by opening and closing one or more vent valves and by applying a single source of fluid flow (e.g., a vacuum) operated at a substantially constant pressure. This can simplify the operation and use of the device by an intended user. | 2013-09-12 |
20130236376 | Microfluidic Test Carrier for Apportioning a Liquid Quantity Into Subquantities - A microfluidic test carrier having a substrate, covering layer, and capillary structure formed in the substrate is provided. The capillary structure is enclosed by the substrate and covering layer and comprises a receiving chamber, sample chamber and connection channel between the receiving and sample chambers. The receiving chamber has two boundary surfaces and a side wall, wherein one boundary surface forms the bottom and the other forms the cover. The receiving chamber has a surrounding venting channel and dam between the receiving chamber and venting channel. The dam and venting channel form a capillary stop configured as a geometric valve, through which air from the receiving chamber can escape into the venting channel. The connecting channel between the venting channel outflow and sample chamber inflow controls fluid transport from the receiving chamber into the sample chamber. The capillary stop is configured to prevent autonomous fluid transport from the receiving chamber. | 2013-09-12 |
20130236377 | APPARATUS FOR PERFORMING A REACTION IN A DROPLET AND METHOD OF USING THE SAME - An apparatus for processing a biological and/or chemical sample in a liquid droplet is provided. The apparatus includes a processing compartment, a base and at least one circumferential wall. The processing compartment is defined by at least a part of the base, at least a part of the circumferential wall and an inlet member. The inlet member is located on top of the processing compartment, and includes at least one droplet inlet channel, which extends through the inlet member and includes a contraction between the inlet opening of the droplet inlet channel to the environment and the outlet opening to the processing compartment. | 2013-09-12 |
20130236378 | Selective Recovery of Manganese and Zinc From Geothermal Brines - This invention relates to a method for the selective recovery of manganese and zinc from geothermal brines that includes the steps of removing silica and iron from the brine, oxidizing the manganese and zinc to form precipitates thereof, recovering the manganese and zinc precipitates, solubilizing the manganese and zinc precipitates, purifying the manganese and zinc, and forming a manganese precipitate, and recovering the zinc by electrochemical means. | 2013-09-12 |
20130236379 | PROCESSES FOR MAKING HIGH IRON CONTENT STABLE FERRIC CHLORIDE SOLUTIONS - Processes for forming high iron content ferric chloride solutions, reconstituting ferric chloride solutions, and transporting the stable ferric chloride solutions with the high iron content are disclosed. | 2013-09-12 |
20130236380 | PALLADIUM SOLID SOLUTION CATAYST AND METHODS OF MAKING - Disclosed are three-way catalysts that are able to simultaneously convert nitrogen oxides, carbon monoxide, and hydrocarbons in exhaust gas emissions into less toxic compounds. Also disclosed are three-way catalyst formulations comprising palladium (Pd)-containing oxygen storage materials. In some embodiments, the three-way catalyst formulations of the invention do not contain rhodium. Further disclosed are improved methods for making Pd-containing oxygen storage materials. The relates to methods of making and using three-way catalyst formulations of the invention. | 2013-09-12 |
20130236381 | DENITRATION CATALYST COMPOSITION AND METHOD OF DENITRATION USING SAME - A denitration catalyst composition to efficiently and reductively remove nitrogen oxides from exhaust gas of a boiler or an internal combustion engine operated in lean-combustion, such as a gasoline engine, a diesel engine, by carbon monoxide and hydrocarbons; and a denitration method using the catalyst composition. In the denitration catalyst composition, a precious metal element having Rh as an essential component is supported on a zirconium oxide-based carrier formed by condensing or mixing primary particles having a zirconium oxide as a main component, and further a cerium-containing oxide (B) is present at the surface of the zirconium oxide-based carrier and at the gap of the secondary particles; and a denitration method characterized in that exhaust gas containing NO, CO and O | 2013-09-12 |
20130236382 | ZEOLITE SCR CATALYSTS WITH IRON OR COPPER - Cu/mordenite catalysts were found to be highly active for the SCR of NO with NH | 2013-09-12 |
20130236383 | Use Of Hydroxypyridones Or Salts Thereof For Stabilizing Hydrogen Peroxide Or Hydrogen Peroxide Donor Substances - A description is given of the use of hydroxypyridones or the salts thereof for stabilizing hydrogen peroxide or hydrogen peroxide donor substances. The stabilization takes place preferably in aqueous compositions. | 2013-09-12 |
20130236384 | METHODS OF PREPARING CLUSTERBORON - New methods are provided for synthesis of ClusterBoron® (B | 2013-09-12 |
20130236385 | METHOD FOR PRODUCING LITHIUM METAL PHOSPHATE - Provided is a method for producing a lithium metal phosphate, and the method comprises initiating and allowing to proceed, in the presence of a polar solvent, a conversion reaction of a lithium ion (Li | 2013-09-12 |
20130236386 | COOLING AND/OR LUBRICATING FLUIDS FOR WAFER PRODUCTION - The invention relates to the use of modified polyglycols for production of cooling and/or lubricating fluids, to novel cooling and/or lubricating fluids, to the use of the cooling and/or lubricating fluids in the removal of material, especially in the cutting of wafers, and to wafers produced with the aid of the cutting fluid. | 2013-09-12 |
20130236387 | Methods and Apparatus for Recovery of Silicon and Silicon Carbide from Spent Wafer-Sawing Slurry - Methods, systems, and apparatus are disclosed herein for recovery of high-purity silicon, silicon carbide and PEG from a slurry produced during a wafer cutting process. A silicon-containing material can be processed for production of a silicon-rich composition. Silicon carbide and PEG recovered from the silicon-containing material can be used to form a wafer-saw cutting fluid. The silicon-rich composition can be reacted with iodine containing compounds that can be purified and/or used to form deposited silicon of high purity. The produced silicon can be used in the photovoltaic industry or semiconductor industry. | 2013-09-12 |
20130236388 | BROAD-EMISSION NANOCRYSTALS AND METHODS OF MAKING AND USING SAME - In one aspect, the invention relates to an inorganic nanoparticle or nanocrystal, also referred to as a quantum dot, capable of emitting white light. In a further aspect, the invention relates to an inorganic nanoparticle capable of absorbing energy from a first electromagnetic region and capable of emitting light in a second electromagnetic region, wherein the second electromagnetic region comprises an at least about 50 nm wide band of wavelengths and to methods for the preparation thereof. In further aspects, the invention relates to a frequency converter, a light emitting diode device, a modified fluorescent light source, an electroluminescent device, and an energy cascade system comprising the nanoparticle of the invention. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2013-09-12 |
20130236389 | METHOD FOR INCREASING THE SULFURIC ACID CONCENTRATION OF A SULFURIC ACID SOLUTION - Described is a method of increasing the sulfuric acid concentration of a first aqueous sulfuric acid solution with a sulfuric acid concentration of 82-89% to a concentrated sulfuric acid solution with a sulfuric acid concentration of at least 90%, including evaporating water from the first aqueous sulfuric acid solution in an evaporator vessel to the concentrated sulfuric acid solution, pumping around a mixture of the first aqueous sulfuric acid solution, part of the concentrated sulfuric acid solution, a second aqueous sulfuric acid solution, and hydrogen peroxide through an enameled piping system comprising the evaporator vessel and one or more heaters and pumps, wherein the piping system is operating at a temperature of at least 180° C., and the sulfuric acid concentration of the second aqueous sulfuric acid solution is at least 90%. | 2013-09-12 |
20130236390 | Method For Batchwise Slaking Of Burnt Lime In A Slaker - A method is described for batchwise slaking of burnt lime in a slaker, in which a lime slurry is produced with a greater degree of fineness and prolonged sedimentation time, comprising the following processing steps:
| 2013-09-12 |
20130236391 | MANUFACTURING FACILITY FOR QUICKLIME, AND MANUFACTURING FACILITY AND MANUFACTURING PROCESS FOR SLAKED LIME - A manufacturing facility for quicklime is provided, which can manufacture highly active quicklime by a simple manufacturing facility, and which can also separate and recover, in a high concentration, CO | 2013-09-12 |
20130236392 | Thermochemical Reactors and Processes for Hydrolysis of Cupric Chloride - A thermochemical reactor ( | 2013-09-12 |
20130236393 | HYDROGEN-GENERATING COLLOIDAL SUSPENSION - The use of a colloidal suspension that comprises between 35% and 60% of alkaline metal particles that are suspended in a neutral hydrophobic diluent for producing gaseous hydrogen, as well as a process for producing hydrogen. Also, a hydrogen-generating device and its use. | 2013-09-12 |
20130236394 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER`S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION - This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele. | 2013-09-12 |
20130236395 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY - Heterocyclic compounds of formula (I) useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described. | 2013-09-12 |
20130236396 | NANOPARTICLES PRODUCED FROM RECOMBINANT POLYMERS AND METHODS OF MAKING AND USING THE SAME - Described herein are nanoparticles produced from recombinant polymers. The nanoparticles are substantially uniform in size, which provides numerous advantages with respect to the delivery of bioactive agents to a subject. Methods for making the nanoparticles are also described herein. In one aspect, the nanoparticles are produced by the method comprising: a. providing a solution comprising one or more recombinant polymer in a solvent; b. forming droplets comprising the one or more recombinant polymers and the solvent; c. removing the solvent to produce the nanoparticles; and d. separating the nanoparticles based on size to produce nanoparticles that are substantially uniform in size. Finally, pharmaceutical compositions composed of the nanoparticles and methods of using the same are also described. | 2013-09-12 |
20130236397 | HAIR SETTING COMPOSITIONS BASED ON T-BUTYL ACRYLATE AND HYDROXYALKYL METHACRYLATE - The present invention relates to copolymers, which comprises, in copolymerized form, between 25 and 80% by weight of tert-butyl(meth)acrylate, 2 to 60% by weight of hydroxyalkyl(meth)acrylate, 10 to 40% by weight of an anionic or anionogenic, free-radically polymerizable, olefinically unsaturated compound which is or comprises methacrylic acid, and, if appropriate, up to 30% by weight of a further free-radically polymerizable, olefinically unsaturated compound. In addition, the present invention relates to the use of such copolymers in cosmetic preparations, and to such cosmetic preparations per se. | 2013-09-12 |
20130236398 | ANTIBODIES THAT BIND TO NANOPARTICLES - Antibodies and antibody fragments that selectively bind to nanoparticles are provided herein. | 2013-09-12 |
20130236399 | APATITE COMPOSITIONS - The present invention relates to an apatite composition comprising 0.001-99.999 wt. % of an apatite and 0.001-99.999 wt. % of a glass carbomer, based on the total weight of the apatite composition. The apatite is preferably a fluoroapatite according to the general formula (I): wherein: M is a cation other than Ca | 2013-09-12 |
20130236400 | Oral Care Product and Methods of Use and Manufacture Thereof - This invention relates to a dual phase mouthwash comprising a hydrophilic phase, a hydrophobic phase, and a hydrotrope, wherein the hydrophilic phase comprises an effective amount of a preservative selected from methylisothiazolinone, sodium benzoate, potassium sorbate, and combinations thereof, as well as to methods of using and of making such compositions. | 2013-09-12 |
20130236401 | PROCESS FOR THE PREPARATION OF INVERSE LATEX OF ACRYLAMIDE-BASED POLYMERS AND COMPOSITION COMPRISING SAID LATEX - Process for the preparation of a composition including an oil phase, an aqueous phase, at least one emulsifying system of water-in-oil (W/O) type, optionally at least one emulsifying system of oil-in-water (O/W) type, in the form of an inverse latex including from 20% to 70% by weight and preferably from 25% to 50% by weight of a branched or crosslinked polyelectrolyte, characterized in that the polyelectrolyte is a copolymer of 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified with acrylamide and optionally one or more monomers chosen from monomers containing a partially or totally salified weak acid function and/or from neutral monomers other than acrylamide, the production process being characterized in that the preparation of the aqueous phase includes the dissolution in the aqueous medium of solid 2-acrylamido-2-methyl propanesulfonic acid before neutralization. Cosmetic, dermopharmaceutical or pharmaceutical composition including the inverse latex directly obtained by the process. | 2013-09-12 |
20130236402 | MIXTURE OF FRAGRANCE COMPOUNDS - The present invention relates to a mixture comprising or consisting of
| 2013-09-12 |
20130236403 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS - Disclosed is a topical skin composition and corresponding methods for its use that includes a topical skin composition comprising an extract from | 2013-09-12 |
20130236404 | SUBSTANCES AND COMPOSITIONS FOR ENHANCING DNA REPAIR AND METHODS OF USE - The invention provides methods of preventing or treating a condition associated with DNA damage in an animal comprising the administration of a substance that interferes with the activity of the CUL4A ubiquitin ligase. The invention also provides a substance that interferes with the activity of CUL4A, as well as compositions comprising the interfering substance and a carrier. The substance of the invention preferably enhances nucleotide excision repair activity in an animal. The invention further provides methods of identifying substances that negatively or positively modulate the expression and/or activity of CUL4A. | 2013-09-12 |
20130236405 | METHOD FOR THE PREPARATION OF COLOURED COSMETIC POWDER PRODUCTS FOR USE ON THE SKIN OF THE EYES, FACE AND BODY - The present invention relates to a new method for the production of coloured cosmetic powders having a solid and creamy consistency for use on the skin of the eyes, face and body, to the powders of a solid and creamy consistency obtained with said production method and to their use as a cosmetic. | 2013-09-12 |
20130236406 | COSMETIC COMPOSITIONS BASED ON A SUPRAMOLECULAR POLYMER, A HYPERBRANCHED FUNCTIONAL POLYMER, A LIGHT SILICONE FLUID AND A COPOLYMER OF A SILICONE RESIN AND A FLUID SILICONE - The present invention relates to a cosmetic composition and method for making up and/or enhancing the appearance of a keratinous substrate, comprising at least one supramolecular polymer, at least one detackifying ingredient which is a hyperbranched functional polymer, at least one fatty phase ingredient(s), at least one light silicone fluid other than the fatty phase ingredient(s), and at least one copolymer containing a silicone resin segment and a fluid silicone segment. The compositions of the present invention may optionally contain at least one functional filler, at least one wax and at least one colorant. | 2013-09-12 |
20130236407 | COSMETIC COMPOSITION BASED ON A SUPRAMOLECULAR POLYMER AND A HYPERBRANCHED FUNCTIONAL POLYMER - The present invention relates to a cosmetic composition and method for making up and/or enhancing the appearance of a keratinous substrate, comprising at least one supramolecular polymer, at least one detackifying ingredient which is a hyperbranched functional polymer and at least one fatty phase ingredient(s). The compositions of the present invention may optionally contain at least one wax and at least one colorant. | 2013-09-12 |
20130236408 | COSMETIC COMPOSITIONS BASED ON A SUPRAMOLECULAR POLYMER, A HYPERBRANCHED FUNCTIONAL POLYMER, A LIGHT SILICONE FLUID, A COPOLYMER OF A SILICONE RESIN AND A FLUID SILICONE, AND A FUNCTIONAL FILLER - The present invention relates to a cosmetic composition and method for making up and/or enhancing the appearance of a keratinous substrate, comprising at least one supramolecular polymer, at least one detackifying ingredient which is a hyperbranched functional polymer, at least one fatty phase ingredient(s), at least one light silicone fluid other than the fatty phase ingredient(s), at least one copolymer containing a silicone resin segment and a fluid silicone segment and at least one functional filler. The compositions of the present invention may optionally contain at least one wax and at least one colorant. | 2013-09-12 |
20130236409 | COSMETIC COMPOSITION BASED ON A SUPRAMOLECULAR POLYMER, A HYPERBRANCHED FUNCTIONAL POLYMER AND A POLYETHYLENE WAX - The present invention relates to a cosmetic composition and method for making up and/or enhancing the appearance of a keratinous substrate, comprising at least one supramolecular polymer, at least one detackifying ingredient which is a hyperbranched functional polymer, at least one fatty phase ingredient(s) and at least one polyethylene wax. The compositions of the present invention may optionally contain at least one colorant. | 2013-09-12 |
20130236410 | MASCARA COMPOSITIONS CONTAINING AN OIL-DISPERSIBLE MICRONIZED WAX AND A WATER-DISPERSIBLE WAX - The invention relates to a composition comprising at least one water-dispersible wax and at least one oil-dispersible micronized wax which, if desired, can be prepared at room temperature. | 2013-09-12 |
20130236411 | COSMETIC COMPOSITION, HAIR COSMETIC AND HAIR TREATMENT COSMETIC - The present invention relates to a cosmetic composition comprising: a copolymer having a constituent unit corresponding to (A) a vinyl monomer having a carboxyl group in a structure and a constituent unit corresponding to (B) a vinyl monomer represented by the following formula (1); a cationic surfactant; a higher alcohol; and a silicone oil: | 2013-09-12 |
20130236412 | Hair or Skin Conditioning Compositions Comprising Hydrophobically Modified Amido Silicone Copolyol - Disclosed are hair or skin conditioning compositions comprising by weight: (a) from about 0.1% to about 10% of a thickening polymer system; (b) from about 0.1% to about 8.0% of a surfactant system selected from the group consisting of cationic surfactant, nonionic surfactant, and mixtures thereof; (c) from about 0.1% to about 10% of a hydrophobically modified amido silicone copolyol; and (d) an aqueous carrier; wherein the composition has a transmittance of 25% or more and/or wherein the composition has a viscosity of from about 1,000 cps to about 50,000 cps and Shear Thinning Index of 30 or more. The compositions are especially suitable for hair care products such as hair conditioning products for rinse-off/leave-on use. | 2013-09-12 |
20130236413 | HAIR CONDITIONING COMPOSITION - The present invention is a hair conditioning composition includes approximately 40,000 IU of Vitamin E oil from 2 fl. oz., approximately 2 fl. oz. of 100% pure Australian tea tree oil, approximately 4 fl. oz. of Jojoba oil, approximately 32 oz. of pure extra virgin organic coconut oil with 62 percent MCT's and approximately 4 fl. oz. of 100 percent cold pressed sweet almond oil. The hair conditioning composition also includes approximately 4 fl. oz. of 100 percent pure Vitamin E, approximately 16 fl. oz. of cold pressed paraben free hexane free castor oil, approximately 16 fl. oz. of 100 percent moisturizing sweet almond oil and a plurality of avocados and whole aloe Vera plants weighing approximately 10 pounds of 100 percent pure fresh cut whole grown aloe Vera fresh plants. | 2013-09-12 |
20130236414 | ODOR-CONTROLLING BODILY FLUID ABSORBER - An odor-controlling bodily fluid absorbent member comprises (a) an absorbent material or substrate; and (b) a halo active aromatic sulfonamide compound of Formula (I): | 2013-09-12 |
20130236415 | MICROORGANISM AND DEODORIZER CONTAINING THE SAME - Thermophilic microorganisms having a deodorizing ability for short chain fatty acids, which are the offensive odor components, are provided. Disclosed are thermophilic microorganisms having a deodorizing ability for short chain fatty acids, which belong to | 2013-09-12 |
20130236416 | SURFACE MODIFIED COLLOIDAL PARTICLES - The present invention generally relates to surface modified colloidal particles. The invention further relates to methods of preparing and methods of using the same. | 2013-09-12 |
20130236417 | LIGANDS FOR ODOR RECEPTORS AND OLFACTORY NEURONS - The disclosure provides compounds useful as insect repellents and compositions comprising such repellents. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules. | 2013-09-12 |
20130236418 | Immunomodulatory Methods and Systems for Treatment and/or Prevention of Aneurysms - Immunomodulatory agents, T cell, compositions, methods and systems for treating and/or preventing an aneurysm and/or a condition associated thereto in an individual. | 2013-09-12 |
20130236419 | COMPOSITIONS AND METHODS RELATED TO ATTENUATED STAPHYLOCOCCAL STRAINS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2013-09-12 |
20130236420 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS - The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin. | 2013-09-12 |
20130236421 | ORAL DOSAGE COMPOSITION - The present invention is an oral dosage composition for prevention and treatment of hepatic inflammation such as NASH. The present invention is an oral dosage composition for prevention or treatment of hepatic inflammation, contains the radical scavenging active spirulina powder effective in preventing, ameliorating, and curing NASH or the like. | 2013-09-12 |
20130236422 | PHARMACEUTICALLY COMPATIBLE METHOD FOR PURIFYING INTACT BACTERIAL MINICELLS - The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 10 | 2013-09-12 |
20130236423 | OLIGOSACCHARIDE MIXTURE AND FOOD PRODUCT COMPRISING THIS MIXTURE, ESPECIALLY INFANT FORMULA - The invention discloses an oligosaccharide mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide, 5-90 wt % of at least one neutral oligosaccharide, 2-50 wt % of at least one sialylated oligosaccharide, and/or 5-70 wt % of at least one fucosylated oligosaccharide. The invention also discloses a food product, especially an infant formula, comprising said oligosaccharide mixture. | 2013-09-12 |
20130236424 | OLIGOSACCHARIDE COMPOSITION FOR TREATING ACUTE RESPIRATORY TRACT INFECTIONS - The inventions discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in preventing acute respiratory infections (ARI) and/or relieving symptoms of said ARI infections. Preferably said composition is a starter infant formula. Said acute respiratory infection is in particular bronchiolitis or otitis. | 2013-09-12 |
20130236425 | COMPOSITIONS AND METHODS FOR CXCR4 SIGNALING AND UMBILICAL CORD BLOOD STEM CELL ENGRAFTMENT - The present invention provides for enhancing engraftment by co-infusing at least two partially HLA matched umbilical cord blood (“UCB”) units. The invention further provides for positive C3a mediated priming on responsiveness to doses of SDF-1 and C3a induced incorporation of CXCR4 in membranes in HSC and progenitors. The invention further provides for enhancing the homing of UCB HSC and progenitors via the SDF-1/CXCR4 pathway and that C3a and LL-37 are useful for this method. It is also disclosed herein that fragments of C3a (e.g., des-Arg) are effective in the methods of the invention, including enhancing homing of HSPCs to BM. The invention further encompasses the disclosure herein of NFAT1 regulation post-transcriptionally by both mir-184 and IFN-γ. The present invention further provides for measuring and using differences between UCB and adult CD4+/45RA+ T-cells as a means of defining strategies to enhance optimal allogeneic stem cell transplantation outcomes. The present invention further provides methods for maintaining IL-2 production in the absence of NFAT1 normal protein levels. | 2013-09-12 |
20130236426 | USE OF DECORIN FOR INCREASING MUSCLE MASS - The invention concerns decorin for increasing muscle mass, particularly in the treatment of muscular dystrophies. | 2013-09-12 |
20130236427 | Topical Dermal Formulations and Methods of Personalized Treatment of Skin - Personalized skin-specific topical formulations containing conditioned medium obtained from cultures of fibroblasts has been developed. Unlike other topical formulations, these formulations are specific for the recipient-skin type specific, and conditioned medium is obtained from a subject with desired skin characteristics. For example, since African American skin is known to wrinkle less and later than Caucasian skin, conditioned medium may be obtained from African American skin for application to pale skin. In another embodiment, the fibroblasts are obtained from young skin for administration to older skin. In still another embodiment, the fibroblasts are obtained from skin that does not suffer from acne or discoloration, for application to skin that is prone to acne or discoloration. Examples of skin donor selection criteria include delayed wrinkling, small pores, resistance to sunburn, resistance to acne, uniform coloration or lack of blotching or age spots and good moisture retention. | 2013-09-12 |
20130236428 | Reprogramming of Aged Adult Stem Cells - Reprogramming of mammalian stem cells including aged human adult stem cells of all types with young adult stem cell's supernatant-intracellular matrix, bioactive lipids and or microvesicules in a single step or as a secondary two step process using oocyte supernatant, its intracellular matrix and/or cellular components are disclosed to accomplish a gene erasure and reprogramming. This invention focuses on reprogramming and/or reactivating genes that are active and involved in youthful adult stem cell function, within aged adult stem cells that have been previously collected by and/or stored for patients who are 40 years and older. The process is accomplished by using the natural unaltered young adult stem cell fluid and its cellular components. | 2013-09-12 |
20130236429 | ENGINEERED VASCULAR ADIPOSE TISSUE - Embodiments of the invention relate to methods, compositions and kits for the in vivo formation of vascularized new adipose tissue in a subject. Combination of endothelial progenitor cells (EPCs) and mesenchymal progenitor cells (MPCs) implanted in vivo in a subject work synergistically to promote the formation vascularized new adipose tissue. | 2013-09-12 |
20130236430 | PROLIFERATION, SEPARATION AND TRANSPLANTATION OF INHIBITORY NEURON PROGENITORS AND PROLIFERATION PROMOTING SUBSTANCES FOR THE PROGENITORS - Those provided here are an Activin A-containing solution for making inhibitory neuron progenitors proliferate, a method for culturing the inhibitory neuron progenitors using this solution, a method for separating the inhibitory neuron progenitors and the inhibitory neurons using an Activin A receptor Acvr1 expression as an index, a method for transplanting thus separated cells to the brain surface, and a method for screening a factor for making the inhibitory neuron progenitors proliferate. | 2013-09-12 |
20130236431 | Compositions and Methods for Tissue Engineering, Tissue Regeneration and Wound Healing - In accordance with certain embodiments of the present disclosure, a kit is described. The kit includes primed living cells joined to and at least partially within a three-dimensional hydrogel structure and an isolated polypeptide having the carboxy-terminal amino acid sequence of an alpha Connexin, or a conservative variant thereof, wherein the polypeptide does not include the full length alpha Connexin protein. | 2013-09-12 |
20130236432 | METHOD AND DEVICE FOR MULTIPLYING AND DIFFERENTIATING CELLS IN THE PRESENCE OF GROWTH FACTORS AND OF A BIOLOGICAL MATRIX OR OF A SUPPORTING STRUCTURE - The invention relates to an in-vitro and in-vivo method for multiplying and differentiating cells, during which the growth process of the cells is initiated or terminated and structurally directed by the use of growth factors thrombopoietin (TPO) and/or erythropoietin (EPO), and/or growth hormone (GH), particularly human growth hormone (HGH), and/or somatostatin and/or leukemia inhibitory factor (LIF) and/or ciliary neurotropic factor (CNTF). The invention also relates to a biological matrix or supporting structure containing the aforementioned growth factors, and to a method and device for the production thereof and for carrying out the inventive method. | 2013-09-12 |
20130236433 | METHODS, COMPOSITIONS, CELLS, AND KITS FOR TREATING ISCHEMIC INJURY - The methods, compositions, cells and kits described herein are based on the discovery that stem cells, when injected into ischemic tissue of mammals, can be protected by preconditioning of the ischemic tissue with hypoxia-regulated human VEGF and human IGF-1. Methods, compositions, cells and kits for treating tissue injured by ischemia or at risk of ischemic injury in a subject are thus described herein. | 2013-09-12 |
20130236434 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS - A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal. | 2013-09-12 |
20130236435 | Somatic Stem Cells - A method of treating brain tissue damage or a neurodegenerative disease in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, and administering to a subject in need thereof an effective amount of the somatic stem cells. | 2013-09-12 |
20130236436 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM - The invention provides methods for obtaining neural stem cells from a mammalian embryonic or inducible pluripotent stem cell population comprising culturing mammalian embryonic or inducible pluripotent stem cells in a cell culture medium having a leukemia inhibitory factor (LIF), an inhibitor of glycogen synthase kinase 3 (GSK3), and an inhibitor of transforming growth factor β (TGF-β) under suitable conditions and obtaining isolated neural stem cells therefrom. | 2013-09-12 |
20130236437 | COMPOSITIONS, KITS AND METHODS FOR TREATMENT OF CARDIOVASCULAR, IMMUNOLOGICAL AND INFLAMMATORY DISEASES - Compositions, kits, cells and methods for treating cardiovascular (e.g., myocardial ischemia and heart failure), immunological, and inflammatory diseases or disorders involve the use of the mature and precursor sequences of microRNAs 142-5p, 142-3p, 17-5p, 17-3p, 374, and 20a, and of antisense molecules complementary to these sequences, to manipulate processes relevant to, for example, the cardiac response to stress, including survival signaling, angiogenesis, stem cell differentiation along muscle or vascular lineages, and repression or promotion of cardiac myocyte growth. Also described are methods to treat cardiovascular, immunological and inflammatory diseases by engineering cells containing specific micro-RNAs or antagomirs against specific mRNAs. The engineered cells can then be used to treat patients with such diseases by autologous stem cell therapy. | 2013-09-12 |
20130236438 | Composition for Treating Phonatory and Olfactory Apparatus Disorders - A composition is described consisting of coenzyme Q10, vitamin A and suitable excipients for treating phonatory and olfactory apparatus disorders, such as anosmia and dysosmia. | 2013-09-12 |
20130236439 | ENZYME-ACTIVATED COLLAGEN AND TISSUE MATRICES - Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include enzyme-activated acellular tissue matrices that facilitate regrowth of the damaged tissue. | 2013-09-12 |
20130236440 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-09-12 |
20130236441 | METHODS OF TREATING AND PREVENTING THROMBOTIC DISEASES USING ASK1 INHIBITORS - A method of treating or preventing a thrombotic disease in a subject in need thereof comprises administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of an apoptosis signal regulating kinase 1 (ASK1) protein. A method of identifying an inhibitor of an apoptosis signal regulating kinase 1 (ASK1) protein useful for treating or preventing a thrombotic disease, comprising (a) contacting a candidate agent with a test sample comprising the ASK1 protein, and (b) comparing the ASK1 protein activity in the test sample with the ASK1 protein activity in a control sample that has not been contacted with the candidate agent, whereby a decrease in the ASK1 protein activity in the test sample compared with the control sample indicates that the candidate agent is an ASK1 inhibitor. | 2013-09-12 |
20130236442 | IDURONATE-2-SULFATASE AND USE THEREOF - Disclosed is a modified iduronate-2-sulfatase (IDS) gene constructed by inserting the nucleotide of SEQ ID NO: 2 into a wild-type IDS gene. In addition to being negatively charged, the improved IDS enzyme encoded by the modified gene exhibits a sufficient retention time in blood to target the bone, so that it is more effective for treating Hunter syndrome. | 2013-09-12 |
20130236443 | SURFACE PROTECTION OF EXPOSED BIOLOGICAL TISSUES - The invention relates to a biodegradable barrier network comprising at least two macromolecular substances, one being anionic and the other one cationic. The invention also relates to applicators and kits comprising components to be used to create said biodegradable barrier network. The invention also relates to the use of said applicator or kit in therapy, such as in medicine, veterinary medicine and horticulture. | 2013-09-12 |
20130236444 | TREATMENT OF MIGRAINE HEADACHE WITH DIFFUSION OF TOXIN IN NON-MUSCLE RELATED FORAMINAL SITES - A method for treating a patient with migraine headache includes administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form. The administration includes extramuscular injection of the neurotoxin to emerging nerve points including foraminal sites for enabling neurotoxin access to concentrated nerve bundles at exit points of the foramina. | 2013-09-12 |
20130236445 | Bromelain proteinases (Bromelainases) as chemotherapeutic agents in treating and/or preventing various types of cancer in a mammal - A method for treating and/or preventing various types of human cancer and neoplastic diseases which is comprised of the administration thereto of an effective amount of Bromelain extract derived from | 2013-09-12 |
20130236446 | TREATMENT OF MIGRAINE HEADACHE WITH DIFFUSION OF TOXIN IN NON-MUSCLE RELATED AREAS OF THE MOUTH - A method for treating a patient with migraine headache includes administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form. The administration includes intra-oral extramuscular injection of the neurotoxin in a foramina of the sphenopalatine ganglion for enabling diffusion of the neurotoxin to the ganglion with the administration being on the trigeminal cervical system, enabling axonal transport of the neurotoxin from distal to central sites. | 2013-09-12 |
20130236447 | COGNITIVE FUNCTION - Inhibition of eIF-2α phosphorylation can be used to improve cognitive function and/or to treat dementia, including Alzheimer's Disease. In particular, this can be achieved by inhibiting the kinase activity of PKR in a non-toxic manner. | 2013-09-12 |
20130236448 | CONCENTRATED POLYPEPTIDE FORMULATIONS WITH REDUCED VISCOSITY - The present invention relates to polypeptide formulations with reduced viscosity and methods of making and using polypeptide formulations with reduced viscosity. | 2013-09-12 |
20130236449 | METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY - The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule. | 2013-09-12 |
20130236450 | Methods Using Lipoprotein-Associated Phospholipase A2 in an Acute Care Setting - This invention relates to methods for using Lipoprotein-associated Phospholipase A2 (Lp-PLA2) to care for subjects in an acute care setting. Specifically, Lp-PLA2 can be used determine if a subject having a vascular event, such as a stroke or heart attack, will benefit from therapy in the acute care setting. Moreover, it relates to methods of assessing risk and severity of a stroke by evaluating Lp-PLA2 levels alone or in combination with other assessments. In addition the invention relates to methods of using Lp-PLA2 to assess the functional outcome in a subject having a vascular event such as a stroke or heart attack. | 2013-09-12 |
20130236451 | ANTIBODIES DIRECTED AGAINST AMYLOID-BETA PEPTIDE AND METHODS USING SAME - Antibodies directed to the C-terminal side of β-amyloid peptide and methods of using these antibodies for diagnosing and treatment of Alzheimer's disease and Aβ peptide associated diseases are described. | 2013-09-12 |
20130236452 | ANTIBODIES SPECIFIC FOR SOLUBLE AMYLOID BETA PEPTIDE PROTOFIBRILS AND USES THEREOF - The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type Aβ 42/40 protofibril comprising N-terminal truncated Aβ forms and (ii) Aβ 42/40 Arc protofibril comprising N-terminal truncated Aβ forms and (b) has no or little cross-reactivity to Aβ 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimer's disease. | 2013-09-12 |
20130236453 | Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors - Methods and compositions for treating or preventing acute graft-versus-host disease (aGVHD) in a subject using miR-155 specific inhibitors are described. | 2013-09-12 |
20130236454 | SUPERIOR EFFICACY OF CD37 ANTIBODIES IN CLL BLOOD SAMPLES - The present invention describes CD37 antibodies, especially A2 and B2, for the treatment of patients with CLL, especially of patients belonging to a “high risk” or “ultra-high risk” group of patients. Those patients are either patients who are refractory to fludarabine treatment or patients who carry a genetic marker which is indicative for poor prognosis or increased risk of treatment failure, e.g. patients with TP53 dysfunction or deletion of chromosome 17p13, or patients after failure to previous anti-CD20 treatment. The ability of A2 and B2 to deplete CLL cells is high both in patient samples derived from patients with normal risk and with increased risk (“high risk” patients) and clearly superior to that of rituximab and alemtuzumab. | 2013-09-12 |
20130236455 | COMPOSITIONS AND METHODS COMPRISING GLYCYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES - Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. | 2013-09-12 |
20130236456 | IMMUNOGLOBULIN Fc FRAGMENT TAGGING ACTIVATION OF ENDOGENOUS CD4 AND CD8 T CELLS AND ENHANCEMENT OF ANTITUMOR EFFECTS OF LENTIVECTOR IMMUNIZATION - A lentivector has been engineered to express a fusion antigen composed of hepatitis B surface protein (HBsAg) and IgG2a Fc fragment (HBS-Fc-Iv) to increase both the magnitude of CD8 response and to induce effective co-activation of CD4 T cells. Immunization with this HBS-Fc-Iv caused significant regression of established tumors. Immunological analysis revealed that, compared to HBS-Iv without the Fc fragment, immunization with HBS-Fc-Iv markedly increased the number of functional CD8 and CD4 T cells and the level of Th1/Tc1-like cytokines in the tumor, while substantially decreasing the Treg ratio. The favorable immunologic changes in tumor lesions and the improvement of antitumor effects from HBS-Fc-Iv immunization were dependent on the CD4 activation, which was Fc receptor mediated. Adoptive transfer of the CD4 T cells from the HBS-Fc-Iv immunized mice could activate endogenous CD8 T cells in an IFNγ-dependent manner. Endogenous CD4 T cells can be activated by lentivirus expressing Fc-tagged antigen to provide another layer of help, i.e., creating a Th1/Tc1 like pro-inflammatory milieu within the tumor lesion to help the effector phase of immune responses to enhance the antitumor effect. | 2013-09-12 |